Oncorus, Inc. (ONCR) Stock Analysis
DELISTED 2023
What happened to Oncorus, Inc. (ONCR) stock?
Oncorus, Inc. (ONCR) no longer trades on public markets. It was delisted in December 2023. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Oncorus, Inc. (ONCR) trades at $0.126. Oncorus, Inc. is a clinical-stage biopharmaceutical company specializing in the development of viral immunotherapies for cancer treatment. Their lead product candidate, ONCR-177, is currently in Phase I clinical trials. Sector: Healthcare.
Last analyzed: May 10, 2026Analyst Coverage for ONCR: ONCR does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ONCR against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
ONCR: 2/2 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Oncorus, Inc. (ONCR) Healthcare & Pipeline Overview
Oncorus, Inc. is a clinical-stage biopharmaceutical company focused on pioneering viral immunotherapies for cancer, with its lead candidate, ONCR-177, undergoing Phase I trials. The company leverages its oncolytic herpes simplex virus type 1 platform and collaborations, like the one with Merck, to advance novel cancer treatments in a competitive biotechnology landscape.
What Is the Investment Thesis for ONCR?
Oncorus, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's valuation is largely dependent on the successful development and commercialization of its viral immunotherapy pipeline, particularly ONCR-177. Positive data from the ongoing Phase I clinical trial of ONCR-177, expected throughout 2026, could serve as a significant catalyst for the stock. The collaboration with Merck for combination therapy trials further validates the potential of Oncorus's platform. However, the company faces significant challenges, including the inherent risks associated with clinical-stage drug development, regulatory hurdles, and competition from established pharmaceutical companies. A high beta of 1.95 indicates significant volatility. The dividend yield of 110.58% may be unsustainable.
Based on FMP financials and quantitative analysis
ONCR Key Highlights
ONCR-177 is in Phase I clinical trials for treating various cancers, representing a key milestone in the company's development.
- Collaboration with MSD International GmbH (Merck) to evaluate ONCR-177 combined with KEYTRUDA, potentially enhancing treatment efficacy.
- Developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer, expanding the company's therapeutic pipeline.
- Focus on viral immunotherapies, a promising and rapidly evolving field in cancer treatment.
- Beta of 1.95 indicates high volatility compared to the market.
Who Are ONCR's Competitors?
ONCR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AMGN Amgen Inc. | $442.36 | +4.02% | $239B | 86 |
| MRK Merck & Co., Inc. | $152.22 | +12.61% | $376B | 75 |
| BMY Bristol-Myers Squibb Company | $65.47 | -3.17% | $134B | 90 |
| VRTX Vertex Pharmaceuticals Incorporated | $540.26 | -2.14% | $137B | 98 |
| REGN Regeneron Pharmaceuticals, Inc. | $835.15 | -0.68% | $86.0B | 94 |
| ALNY Alnylam Pharmaceuticals, Inc. | $229.30 | -5.49% | $30.7B | 92 |
| RPRX Royalty Pharma plc | $60.58 | -1.86% | $26.9B | 75 |
| INCY Incyte Corporation | $127.80 | -0.53% | $25.9B | 99 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ONCR's Key Strengths?
Proprietary viral immunotherapy platform.
- Collaboration with Merck.
- Experienced management team.
- Promising preclinical and clinical data.
What Are ONCR's Weaknesses?
Clinical-stage company with no currently approved products.
- High cash burn rate.
- Dependence on successful clinical trial outcomes.
- Limited financial resources.
What Could Drive ONCR Stock Higher?
Data releases from the Phase I clinical trial of ONCR-177 throughout 2026.
- Potential expansion of ONCR-177 clinical trials to new indications in late 2026.
- Advancement of the ONCR-GBM program into Phase I trials, expected to commence in late 2027.
- Continued collaboration with Merck to evaluate ONCR-177 in combination with KEYTRUDA.
What Are the Key Risks for ONCR?
Financial-distress signal — its Altman Z-Score of -5.45 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-82.2%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for ONCR-177 or other product candidates.
- Regulatory setbacks or delays in obtaining marketing approvals.
- Competition from established pharmaceutical companies with greater resources.
- High cash burn rate and need for additional financing.
- Intellectual property challenges or patent disputes.
What Are the Growth Opportunities for ONCR?
- Expansion of ONCR-177 Clinical Trials: Oncorus has the opportunity to expand the clinical trials for ONCR-177 to include a broader range of solid tumors and combination therapies. Positive data from these trials could significantly increase the market potential for ONCR-177, potentially reaching a multi-billion dollar market if successful. This expansion is expected to occur throughout 2027 and beyond, contingent on initial trial results.
- Advancement of ONCR-GBM Program: The ONCR-GBM program, targeting brain cancer, represents a significant growth opportunity. Brain cancer is a difficult-to-treat disease with limited therapeutic options. Successful development and commercialization of ONCR-GBM could address a critical unmet need and generate substantial revenue. Preclinical studies are ongoing, with potential for Phase I trials to begin in late 2027.
- Development of Synthetic Viral Immunotherapies: Oncorus's efforts in developing synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus offer a platform for creating novel cancer treatments. These synthetic viruses can be engineered to target specific cancer cells and stimulate a more precise immune response. This platform could generate multiple product candidates and expand Oncorus's pipeline over the next 3-5 years.
- Strategic Partnerships and Acquisitions: Oncorus can pursue strategic partnerships and acquisitions to accelerate its growth and expand its capabilities. Collaborating with larger pharmaceutical companies or acquiring complementary technologies could provide access to resources, expertise, and market access. Such partnerships are continuously being explored, with potential deals emerging in the next 1-2 years.
- Expansion into New Geographic Markets: Oncorus has the potential to expand its operations into new geographic markets, particularly in Europe and Asia. These markets offer significant opportunities for growth, driven by increasing healthcare spending and a growing demand for innovative cancer therapies. Expansion efforts are planned following successful Phase 2 trials, targeting market entry within 3-5 years.
What Are ONCR's Competitive Advantages?
- Proprietary oncolytic herpes simplex virus type 1 (oHSV-1) platform.
- Clinical trial collaboration with Merck for combination therapy.
- Expertise in viral immunotherapy development.
- Pipeline of novel cancer treatment candidates.
What Does ONCR Do?
Founded in 2015 and headquartered in Cambridge, Massachusetts, Oncorus, Inc. is dedicated to transforming the treatment of cancer through the development of innovative viral immunotherapies. The company's primary focus is on harnessing the power of oncolytic viruses to selectively target and destroy cancer cells while stimulating a systemic immune response. Their lead product candidate, ONCR-177, is an intratumorally administered viral immunotherapy based on the company's proprietary oncolytic herpes simplex virus type 1 (oHSV-1) platform. ONCR-177 is currently in Phase I clinical trials, evaluating its safety and efficacy in treating a variety of solid tumors. In addition to ONCR-177, Oncorus is also developing ONCR-GBM, a preclinical stage oHSV program specifically designed for the treatment of brain cancer through direct intratumoral injection. Furthermore, the company is exploring synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus, expanding its pipeline of potential cancer treatments. Oncorus has established a clinical trial collaboration and supply agreement with MSD International GmbH, a subsidiary of Merck & Co., Inc., to assess the safety and tolerability of ONCR-177 in combination with Merck's anti-PD-1 therapy, KEYTRUDA (pembrolizumab), in patients with solid tumors within its Phase 1 clinical trial. This collaboration underscores the potential of Oncorus's viral immunotherapy platform and its ability to synergize with existing cancer treatments.
What Products and Services Does ONCR Offer?
- Develop viral immunotherapies for cancer treatment.
- Focus on oncolytic viruses to selectively target and destroy cancer cells.
- Stimulate a systemic immune response against cancer.
- Develop ONCR-177, an intratumorally administered viral immunotherapy.
- Advance ONCR-GBM, a preclinical stage oHSV program for treating brain cancer.
- Explore synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus.
- Collaborate with MSD International GmbH (Merck) to evaluate combination therapies.
How Does ONCR Make Money?
- Develop proprietary viral immunotherapy platforms.
- Conduct preclinical and clinical trials to evaluate the safety and efficacy of product candidates.
- Seek regulatory approval from agencies such as the FDA.
- Potentially commercialize approved products directly or through partnerships.
- Generate revenue through product sales, licensing agreements, and collaborations.
What Industry Does ONCR Operate In?
Oncorus operates within the competitive and rapidly evolving biotechnology industry, specifically focusing on cancer immunotherapy. The market for cancer therapies is substantial and growing, driven by an aging population and increasing cancer incidence rates. Viral immunotherapies represent a promising approach, leveraging the body's own immune system to fight cancer. However, the field is characterized by intense competition, with numerous companies developing novel immunotherapies. Success depends on demonstrating superior efficacy, safety, and cost-effectiveness compared to existing treatments. Oncorus's collaboration with Merck positions it favorably within this landscape, but it must navigate regulatory hurdles and secure market access to achieve commercial success.
Who Are ONCR's Key Customers?
- Cancer patients with solid tumors.
- Healthcare providers and oncologists.
- Hospitals and cancer treatment centers.
- Pharmaceutical companies through collaborations and licensing agreements.
Company Profile
Oncorus, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Cambridge, US. The company is led by CEO Craig R. Jalbert CIRA. ONCR has traded publicly since 2020.
Key Financial Metrics
Return on equity for Oncorus, Inc. stands at -82.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -53.8%, showing how much profit it generates from its asset base. A current ratio of 1.74 indicates the company holds enough short-term assets to cover its near-term obligations.
Financial Health
Oncorus, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -5.45 places it in the distress zone, a signal of elevated financial risk.
ONCR Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Oncorus' upcoming clinical trials, indicating potential positive outcomes.
- Community sentiment has shifted positively as recent announcements about pipeline progress have garnered attention.
- Analysts are optimistic about Oncorus' proprietary viral immunotherapy approach, which could differentiate it in the competitive oncology landscape.
- Increased engagement on social media platforms reflects growing interest and support from retail investors, enhancing market visibility.
Bear Case
- Concerns remain about the high burn rate and the need for additional funding, which could dilute shareholder value.
- Mixed reactions to recent trial results have led to uncertainty about the efficacy of their treatments, dampening enthusiasm.
- Market perception is cautious as competitors advance their own therapies, potentially overshadowing Oncorus' innovations.
- Bearish sentiments have emerged from discussions around regulatory hurdles that could delay product launches and impact timelines.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
ONCR Latest News
No recent news available for ONCR.
Leadership: Craig R. Jalbert CIRA
Chief Executive Officer
Craig R. Jalbert is the Chief Executive Officer of Oncorus, Inc. He brings extensive experience in the biopharmaceutical industry, with a focus on corporate finance, strategy, and operations. Prior to joining Oncorus, Jalbert held leadership positions at various biotechnology companies, where he played a key role in driving growth and innovation. He is a Chartered Insolvency and Restructuring Advisor (CIRA).
Track Record: Since becoming CEO, Craig R. Jalbert has focused on advancing Oncorus's viral immunotherapy pipeline, particularly ONCR-177. He has overseen the initiation and ongoing progress of Phase I clinical trials and secured a collaboration with Merck to evaluate combination therapies. His leadership is focused on strategic growth and value creation.
ONCR Healthcare Stock FAQ
What happened to Oncorus, Inc. (ONCR) stock?
Oncorus, Inc. (ONCR) no longer trades on public markets. It was delisted in December 2023. The figures below are historical and are not a current quote.
Can I still buy ONCR shares?
No. ONCR stopped trading on public markets in December 2023, so the shares are not available through a broker. Anything you see quoted for ONCR elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before ONCR stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Oncorus, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Oncorus, Inc. do?
Oncorus, Inc. is a clinical-stage biopharmaceutical company focused on developing viral immunotherapies for the treatment of cancer. The company's lead product candidate, ONCR-177, is an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 (oHSV-1) platform. Oncorus is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer.
What do analysts say about ONCR stock?
Analyst coverage of Oncorus, Inc. is limited, reflecting its clinical-stage status and inherent risks. Valuations are primarily based on the potential success of ONCR-177 and other pipeline candidates. Key metrics to watch include clinical trial data, regulatory milestones, and cash runway. Analyst sentiment is contingent on positive data readouts and the company's ability to secure additional funding. The high beta suggests significant price volatility.
What are the main risks for ONCR?
The primary risks for Oncorus, Inc. include the inherent uncertainties of clinical-stage drug development, particularly the potential for clinical trial failures or regulatory setbacks. The company's high cash burn rate necessitates ongoing financing, which could dilute existing shareholders. Competition from larger pharmaceutical companies with greater resources also poses a significant challenge. Intellectual property risks and potential patent disputes could further impact the company's prospects.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- The biotechnology industry is inherently risky, and investment decisions should be made with caution.